The System of Infrastructure Ensuring Business Activity in the Market of Mobile Commerce of Russia

Entrepreneurship in the mobile commerce market provides the opportunity to search for new opportunities for companies in the mobile environment. Taking into account the innovative nature of entrepreneurship in the mobile commerce market, it is necessary to form an infrastructure support system, the main tasks of which are: activating business processes in the mobile commerce system by creating the necessary conditions and turning business activities in this area into a real factor of economic growth by adapting the economy to advanced technologies. The article discusses the system of infrastructure support for entrepreneurship in the mobile commerce market as a complex of institutional entities that provide the conditions for implementing the processes of organizing and managing the development of entrepreneurial activities in the mobile commerce market in Russia. Thus, the infrastructure support of small business in the mobile commerce market is a combination of conditions, institutions and mechanisms that ensure the sustainable development and competitiveness of Internet companies in the Internet environment

ФАКТОРЫ РИСКА СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ И ЦЕНТРАЛЬНОЙ ГЕМОДИНАМИКИ У СТУДЕНТОВ-СТАРШЕКУРСНИКОВ

HighlightsThe article examines the prevalence of risk factors for cardiovascular diseases (CVD) and the state of central hemodynamics (CHD) in senior students. Aim. To study the risk factors for CHD and CVD in senior students with the aim of early detection of arterial hypertension (AH) and the implementation of therapeutic and prophylactic measures.Methods. The study involved 223 senior students of medical universities in Moscow aged 20-27 years (the mean age was 22.8±0.17 years). The following cardiovascular risk factors were assessed for each student: age, gender, smoking, physical activity, genetic predispositions; body mass index. The indicators of CHD were studied by volumetric compression oscillometry using a portable automated software-hardware complex for non-invasive research of central hemodynamics (“SHCNIR CHD vco-“Globus” device).Results. The presence of CVD risk factors in senior students was revealed in 52.5% of cases; more than two risk factors were found in 19.3% of cases; 1st degree arterial hypertension (AH) in 11.2% of cases; “white coat hypertension” in 10.8% of cases; genetic predisposition to CVD in 30.0% of cases; overweight in 17.0% of cases; obesity in 5.4% of cases; low physical activity in 23.8% of cases; smoking in 16.1% of cases. An altered CHD profile was found in 62.1% of students. An increase in total peripheral vascular resistance at normal blood pressure levels was noted in 31.8% of cases. Indicators of total peripheral vascular resistance, mean blood pressure, systolic and diastolic blood pressure were significantly higher in the group of students with CHD risk factors.Conclusion. Outpatient follow-up groups should include students with established risk factors for cardiovascular diseases, diagnosed AH, and with altered indicators of CHD. Preventive examinations should include a simple method for studying hemodynamics – compression oscillometry.Основные положенияВ статье исследованы частота факторов риска развития сердечно-сосудистых заболеваний и состояние центральной гемодинамики у студентов старших курсов. Цель. Изучить основные факторы риска сердечно-сосудистых заболеваний (ФР ССЗ) и центральной гемодинамики (ЦГД) у студентов-старшекурсников.Материалы и методы. Обследованы 223 студента старших курсов медицинских вузов Москвы в возрасте 20–27 лет (средний возраст составил 22,8±0,17 года). У каждого студента оценены основные ФР ССЗ: возраст, пол, курение, физическая активность, наследственность, индекс массы тела. Показатели ЦГД исследованы методом объемной компрессионной осциллометрии с помощью портативного автоматизированного программно-аппаратного комплекса неинвазивного исследования центральной гемодинамики (прибор «КАП ЦГ осм-«Глобус»).Результаты. ФР ССЗ выявлены у 52,5% студентов старших курсов, более двух факторов риска обнаружено у 19,3%. Артериальная гипертензия I степени зарегистрирована у 11,2% лиц, артериальная гипертензия «белого халата» – у 10,8%, отягощенная наследственность – у 30,0%, избыточная масса тела – у 17,0%, ожирение – у 5,4%, гиподинамия – у 3,8%, курение – у 16,1% обследованных. Измененный профиль ЦГД обнаружен у 62,1% студентов. Повышение общего периферического сосудистого сопротивления при нормальных уровнях артериального давления определено у 31,8% лиц. Показатели общего периферического сосудистого сопротивления, среднего, систолического и диастолического артериального давления были достоверно выше в группе студентов с ФР ССЗ.Заключение. В группу диспансерного наблюдения необходимо включать студентов не только с установленными ФР ССЗ, выявленной артериальной гипертензией, но и измененными показателями ЦГД. В профилактические осмотры необходимо добавить простой метод исследования гемодинамики – компрессионную осциллометрию

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk